Is HFNC as effective as NIV in reducing respiratory rate and improving respiratory distress within 2 hours in ACPE?
The OPTION trial evaluated IV tenecteplase (0.25 mg/kg) in CT perfusion–selected non-LVO ischemic stroke patients treated 4.5–24 hours after last-known-well. Tenecteplase improved excellent 90-day outcomes (mRS 0–1) but increased symptomatic intracranial hemorrhage, with the benefit–harm balance sensitive to outcome and ...
The HAT and SEDAN scores help estimate symptomatic intracranial hemorrhage risk after stroke thrombolysis. This comparison reviews what each tool measures, when to use them, and the key limitations clinicians should know.
Need a quick, reliable coma scale in real ED chaos? SMS simplifies assessment, while FOUR adds brainstem and respiratory data when it matters most.
The cornerstone of acute ischemic stroke (AIS) management involves timely reperfusion of the ischemic brain tissue. Intravenous thrombolysis with alteplase has been the standard of care for AIS within 4.5 hours of symptom onset, based on pivotal trials such as ...
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
